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Abstract
Objectives
Obstructive sleep apnea (OSA) is among the least studied risk factors for erectile dysfunc-
tion (ED). We aimed to determine ED prevalence in newly-diagnosed OSA patients,
describe their main characteristics and assess continuous positive airway pressure (CPAP)
effects on ED.
Methods
Cross-sectional study assessing ED prevalence in OSA patients and open-label, parallel, pro-
spective randomized controlled trial evaluating 3-month CPAP treatment effects on sexual
function, satisfaction, and psychological, hormonal and biochemical profiles. Male patients
newly diagnosed with moderate/severe OSA (apnea-hypopnea index >20 eventsh−1), aged
18–70 years, attending the sleep unit of a Spanish hospital during 2013–2016 were consid-
ered. A total of 150 patients were recruited (75 randomized ED patients). ED was defined as
scores <25 on International Index Erectile Function 15 test. Wilcoxon’s matched-pairs signed-
ranks and rank-sum tests were used.
Results
ED prevalence was 51%. Patients with ED were older (p<0.001), had greater waist-to-hip
ratios (p<0.001), were more frequently undergoing pharmacological treatment (p<0.001)
and had higher glucose levels (p = 0.024) than non-ED patients. Although significant
increases in erectile function (mean(SD) change: +4.6(7.9); p = 0.002), overall satisfaction
(+1(2.2); p = 0.035), and sexual satisfaction (+2.1(4.3); p = 0.003) were found after CPAP
treatment, only differences in sexual satisfaction (p = 0.027) and erectile function (p = 0.060)
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were found between study arms. CPAP treatment did not impact psychological, hormonal or
biochemical profiles.
Conclusions
This study confirmed the relationship between OSA and ED, suggesting the potential useful-
ness of ED screening in OSA patients, but could not determine conclusively whether CPAP
is an effective stand-alone ED treatment, regardless of positive results on sexual
satisfaction.
Trial registration
ClinicalTrials.gov NCT03086122
Introduction
Obstructive sleep apnea (OSA), defined as the presence of repetitive episodes of upper airway
collapse during sleep, is a common chronic condition affecting 10% of middle-aged men [1].
Although OSA can be asymptomatic, it is usually characterized by intermittent hypoxia, day-
time sleepiness, and an overall decrease in quality of life. OSA has been related to many pathol-
ogies, such as cardiovascular diseases [2], stroke [3] and hypertension [4]. Interestingly, the
vascular implications of recurrent airway obstruction, intermittent hypoxemia and arousal
from sleep, together with OSA-induced hormonal and psychological changes, have been sug-
gested to increase the risk for erectile dysfunction (ED) [5–7].
ED, defined as the persistent inability to attain and maintain an erection sufficient to allow
for satisfactory sexual performance [8], is a frequent phenomenon estimated to be present in
20% of men aged 30–70 years old, with a steep age-related increase in prevalence [9–11]. How-
ever, ED prevalence has been described as being as high as 69% among OSA patients [7], and
in such patients, ED is considered to be a risk factor for future cardiovascular complications.
Few studies to date have assessed whether continuous positive airway pressure (CPAP) treat-
ment, one of the therapeutic options for OSA, could improve ED in OSA patients. Two reviews
of the subject analyzing data through December 2014 concluded that although CPAP could
improve sexual function and sexual satisfaction, randomized controlled trials (RCTs) were
needed to confirm these potential benefits [12,13].
To increase knowledge on OSA-related ED, we first designed a cross-sectional study assess-
ing ED prevalence in newly diagnosed OSA patients, comparing the hormonal, biological and
psychological profiles of OSA patients with and without ED. Next, with the hypothesis that
CPAP treatment could effectively reverse OSA-related ED, improving sexual function, hor-
monal profiles and sexual satisfaction, we designed an RCT randomizing OSA patients with
ED to receive CPAP treatment or not.
Methods
Study design and population
Cross-sectional study considering consecutive male patients newly diagnosed with moderate
to severe OSA, aged 18 to 70 years and in a current relationship who were attending the sleep
unit of Hospital Univ Arnau de Vilanova-Santa Maria, Spain, between April 1st 2013 and July
31th 2016. Followed by an open-label, parallel, prospective RCT, including only those OSA
Erectile dysfunction in obstructive sleep apnea
PLOS ONE | https://doi.org/10.1371/journal.pone.0201930 August 8, 2018 2 / 13
committee of Hospital Univ Arnau de Vilanova
(cea_arnau.lleida.ics@gencat.cat) specifying the
approval code: CEIC-996.
Funding: The authors acknowledge funding from
"Rafael Molla´ y Rodrigo" 2012 clinical research
grant (Fundacio´n investigacio´n Urologı´a,
Asociacio´n Española de Urologı´a, Spain); and,
“SEPAR 2011” research grant (Spanish Society of
Pneumology and Thoracic Surgery - SEPAR). The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
patients that were diagnosed of ED, with a 3-month follow-up ending between September 1st
2013 and September 30th 2016.
Exclusion criteria: previous CPAP treatment; previously diagnosed sleep disorders; patients
with>50% central apneas; Cheyne-Stokes respiration; daytime sleepiness as measured by the
Epworth Sleepiness Scale (ESS) score >10 (S1 Questionnaires); psychophysical inability to
complete questionnaires; uncontrolled or advanced chronic diseases (cardiovascular disease,
multiple sclerosis, Parkinson’s disease, spinal disc disease, schizophrenia, bipolar disorder,
chronic renal failure and inflammatory bowel disease); pelvic surgery (radical prostatectomy);
congenital or acquired malformations (Peyronie’s disease, hypospadias, epispadias, and penile
fracture); hormonal alterations (hypogonadism, hyperprolactinemia, hyper- or hypothyroid-
ism, and Cushing’s disease); and drug abuse (alcohol, cocaine, and heroin).
OSA patients fulfilling inclusion criteria were referred to the Urology Department, where
they were informed about the project and asked to participate. Recruited patients were
assessed for ED and answered to the study questionnaires. Web-based randomization of the
ED patients (non-ED patients did not participate in the RCT) was performed using a secure,
automated, password-protected system based on a permuted block design with a computer
random number generator and a fixed block size of 10. Allocation was revealed only at the
time of each subject randomization. No blinding measures were implemented. The ED
patients were randomly assigned at a 1:1 ratio to immediately begin CPAP treatment (ED
CPAP group) or to postpone CPAP treatment for 3 months (ED non-CPAP group). After-
wards, the recruited patients returned to the sleep unit for additional measurements and
CPAP titration when required. All of the patients included in the RCT were followed up for 3
months and were reassessed in terms of ED-related clinical, biological and psychological
aspects.
The ethics committee of Hospital Univ Arnau de Vilanova approved the study (CEIC-996;
Mar. 27th 2012), and all patients provided written informed consent. The RCT was registered
at ClinicalTrials.gov (NCT03086122). Unfortunately, although the authors believed the trial to
be registered on 2012, a successful registration was not achieved before the inclusion of the
first patient due to administrative mistakes. Nevertheless, this study was performed according
to the protocol submitted for ethical review on Mar. 2012. The authors confirm that all ongo-
ing and related trials for this intervention are registered.
Data collection
OSA was defined by means of a valid complete polysomnography reporting an apnea–hypop-
nea index (AHI) >20 eventsh−1 with50% of central apneas, according to the Spanish Respi-
ratory Society (SEPAR) guidelines [14]. Obstructive apnea was defined as an absence or
reduction (>90%) of airflow lasting10 s in presence of abdominal and thoracic movements.
Obstructive hypopnoea was defined as a reduction (30% to 90%) in airflow lasting10 s asso-
ciated with a decrease in arterial oxygen saturation3% and/or a micro-awakening on the
electroencephalogram, in presence of both thoracic and abdominal movements. The AHI was
defined as the number of episodes of apnea and hypopnea per hour of recording. Central
apneas were defined as an absence airflow lasting at least 10 s in absence of thoracic and
abdominal wall movements. A minimum of 3 hours of satisfactory signal recording was
required to consider the test as valid.
CPAP titration was performed using an auto-CPAP device (Autoset-T, ResMed, Sydney,
Australia) as previously validated by the Spanish Sleep and Breathing Group [15]. Up to two
additional night recordings were attempted if the original recording was unacceptable. The
determination of the optimal pressure was assessed by visually analyzing the pressure curve,
Erectile dysfunction in obstructive sleep apnea
PLOS ONE | https://doi.org/10.1371/journal.pone.0201930 August 8, 2018 3 / 13
which included the periods with a leak lower than 0.4 L/s (90th centile). At-home treatment
was initiated with a fixed CPAP level after the optimal pressure was determined.
ED was assessed by means of the International Index Erectile Function 15 (IIEF15) test
[16], in its Spanish version [17], which allows for the assessment of sexual function broadly
encompassing erectile function, orgasmic function, sexual desire, sexual satisfaction and over-
all satisfaction (S1 Questionnaires). The test was administered by a Urology department physi-
cian. Patients were classified as having ED when their erectile function domain score was less
than 25 points.
Sociodemographic variables, as well as lifestyle habits, clinical background and usual phar-
macological treatment, were recorded using questionnaires. Anthropometric measurements
included weight; height; body mass index (BMI); neck, waist and hip circumferences; and
waist to hip ratio (WHR). Fasting blood samples were obtained between 8:00h and 9:00h a.m.
in the span of few days between recruitment and polysomnography. Serum and plasma sam-
ples were stored at -80˚C. Biochemical profiling included glucose, lipids (triglycerides, total
cholesterol, and high-density lipoprotein (HDL) and low-density lipoprotein (LDL) choles-
terol), creatinine, urate, sodium, potassium, proteins, glutamyl pyruvic transaminase (GPT),
gamma-glutamyl transferase (GGT) and C-reactive protein (CRP). Hormonal profiling
included total testosterone, free testosterone, sex hormone binding globulin (sHBG), prolactin,
luteinizing hormone (LH) and follicle-stimulating hormone (FSH), all measured by RIA
(R&D Systems Europe, Abingdon, UK). Additionally, a basic hemogram was performed.
Blood pressure was routinely measured. Continuous recording of night-time oxygen satura-
tion by means of pulse oximetry was conducted routinely at the time of polysomnography.
Finally, the Self-esteem and Relationship (SEAR) test [18], a self-administered test designed to
specifically evaluate psychosocial aspects associated with ED, was administered to all patients
during their Urology Department visits (S1 Questionnaires). The patients included in the RCT
underwent reassessments of IIEF15 and SEAR, biochemical and hormonal profiles and CPAP-
related variables after 3 months (in the CPAP arm), during a follow-up visit. Fasting blood
samples were obtained between 8:00h and 9:00h a.m. on the same day of the follow-up visit.
Statistical analyses
Means ± standard deviation (SD), medians (IQR) or frequencies (%) were computed to evalu-
ate the differences between OSA patients with and without ED, assessing the significance of
such differences with the chi-square test, independent samples Student’s t test or Mann-Whit-
ney U test, as appropriate. The effects of CPAP treatment in the RCT were assessed on an
intention to treat basis by comparing the differences between baseline and 3-month measure-
ments using Wilcoxon’s matched-pairs signed-ranks test. The comparison of changes between
non-CPAP and CPAP patients was performed by means of Wilcoxon’s rank-sum test. Finally,
as a complementary analysis, multivariate ordered logistic regression models were constructed
to ensure that key variables differing between ED and non-ED patients were not confounding
the results on CPAP treatment effect.
Accepting an alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, 63 subjects were
necessary in each RCT study arm to recognize as statistically significant a 2-unit difference in
the erectile function score (IIEF15) after the intervention. The 2-unit minimal clinically
important difference was defined according to the results by Rosen et al for mild ED patients
[19]. The common SD was assumed to be 4 units. Assuming a 69% prevalence of ED among
OSA patients [7,20], 183 OSA patients needed to be assessed to obtain the required 126 ED
patients. However, although having a randomization goal of 126 ED patients, the study was
stopped at 75. The main reasons for not reaching the recruitment goal were, first, the lower-
Erectile dysfunction in obstructive sleep apnea
PLOS ONE | https://doi.org/10.1371/journal.pone.0201930 August 8, 2018 4 / 13
than-expected prevalence of ED coupled with tight inclusion criteria, causing a very slow
recruitment pace (a planned 2-year study turned out having a 3.5 years recruitment phase);
second, the financial constrains caused by the extended recruitment phase; and third, the need
to avoid biases caused by changes in the personnel assessing the patients.
Data analysis was conducted using Stata software, version 12.1 (StataCorp, College Station,
TX, USA). The threshold for significance was set at 0.05.
Results
Up to 487 newly diagnosed male OSA patients were screened. After excluding patients who
did not meet the inclusion criteria, a total of 150 patients (77 with ED and 73 without ED)
were included in the analyses, and 75 ED patients were randomized (Fig 1).
The prevalence of ED among the OSA patients in our study was 51% (95% CI: 43%-60%).
Table 1 shows the main characteristics of the OSA patients according to ED presence. ED
patients were older, had greater WHRs and were more frequently undergoing pharmacological
treatment than patients without ED. None of the patients reported use of Type 5 phosphodies-
terase inhibitors. No differences in hormonal or biochemical profiles were found, except for
higher glucose levels in ED patients (Table 2). Finally, Table 3 shows IIEF15 and SEAR scores.
The median (IQR) erectile function score for non-ED patients was 29 (27–30), and the total
SEAR score was 78 (71–86). In contrast, ED patients had an erectile function score of 18 (6–
22) and a SEAR score of 62 (50–77).
After randomization 40 patients were treated with CPAP for 3 months with a median
(IQR) CPAP use of 5.3 (3.2–6.0) h/night. Eight non-CPAP and 10 CPAP subjects had no
IIEF15 measurements at the end of the follow-up and were excluded from the primary out-
come analyses. A baseline comparison between study arms revealed no significant differences
except for AHI (mean (SD) eventsh−1: CPAP patients 55.8 (20.6); non-CPAP patients 45.3
(19.2); p = 0.037), although no statistically significant differences were found in the proportion
of severe (AHI > 30 eventsh−1) OSA patients. Significant increases in erectile function (mean
(SD) change: +4.6 (7.9); p = 0.002), sexual satisfaction (mean (SD) change: +2.1 (4.3);
Fig 1. Study flowchart.
https://doi.org/10.1371/journal.pone.0201930.g001
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p = 0.003) and overall satisfaction (mean (SD) change: +1 (2.2); p = 0.035) were found
(Table 4). Between-arm differences in sexual satisfaction changes were statistically signifi-
cant (p = 0.027), while differences in erectile function changes were borderline non-signifi-
cant (p = 0.060). Regardless of statistical significance, dose-response relationships could be
seen for Erectile function and Sexual satisfaction when considering 3 CPAP compliance cat-
egories: non-users, user below median (5.3 h/night) and users above median (Table A in S1
Additional Results). CPAP treatment did not have any relevant impacts on the psychologi-
cal, hormonal or biochemical profiles of ED patients (Tables 5 and 6). Finally, ordered logis-
tic regression adjusting for age, WHR, and use of hypolipidemics, that were the most
differing variables between ED and non-ED patients, showed very similar results (data not
shown).
Table 1. Main characteristics of OSA patients according to erectile dysfunction (ED) presence.
non-ED
n = 73
ED
n = 77
p-value
Age, years 48.7 (1.1) 54.8 (1) <0.001
Body mass index, kgm−2 32.2 (0.6) 33.0 (0.6) 0.274
Waist to hip ratio 0.98 (0.01) 1.04 (0.01) <0.001
Systolic blood pressure, mm Hg 135 (2) 138 (2) 0.271
Diastolic blood pressure, mm Hg 88.3 (1.2) 88.7 (1.4) 0.844
AHI, eventsh−1 46.1 (20.1) 51.6 (20.9) 0.121
Mean SaO2, % 74.4 (9.6) 71.9 (12) 0.174
Minimum SaO2, % 90.5 (9.1) 92.5 (8) 0.171
Time with SaO2 <90%, % 20.2 (21.6) 19.4 (21.5) 0.829
Epworth Sleepiness Scale 9.6 (5.3) 10.2 (5.8) 0.556
Nycturia, n (%) 49 (74%) 49 (72%) 0.776
Employment status, n (%) 0.018
Active 57 (83%) 48 (66%)
Inactive 9 (13%) 11 (15%)
Retired 3 (4%) 14 (19%)
Stable partner, n (%) 65 (89%) 68 (88%) 0.888
Current smoker, n (%) 26 (36%) 27 (35%) 0.853
Current alcohol drinker, n (%) 33 (46%) 32 (43%) 0.643
Pharmacological treatment, n (%) 35 (48%) 59 (77%) <0.001
Diuretics, n (%) 6 (8%) 12 (16%) 0.165
Anticoagulants, n (%) 5 (7%) 11 (14%) 0.140
Antacids, n (%) 9 (12%) 15 (19%) 0.232
Hypolipidemics, n (%) 10 (14%) 28 (36%) 0.001
Beta-blockers, n (%) 4 (5%) 6 (8%) 0.570
Calcium antagonists, n (%) 5 (7%) 12 (16%) 0.092
ACEi, n (%) 14 (19%) 26 (34%) 0.043
Antiarrhythmics, n (%) 0 (0%) 2 (3%) 0.166
Insulin, n (%) 1 (1%) 2 (3%) 0.591
Oral antidiabetics, n (%) 2 (3%) 9 (12%) 0.036
Mean (SD) or n (%) as appropriate. OSA: obstructive sleep apnea; AHI: apnea-hypopnea index; SaO2: oxygen
saturation; ACEi: angiotensin-converting enzyme inhibitors
 Independent samples Student’s t test or chi-square test as appropriate
https://doi.org/10.1371/journal.pone.0201930.t001
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Discussion
In this double-purpose study, we determined an ED prevalence of 51% among newly diag-
nosed OSA patients. Patients with ED were older, had a greater WHR, were more frequently
Table 2. Hormonal and biochemical profiles of OSA patients according to erectile dysfunction (ED) presence.
non-ED
n = 73
ED
n = 77
p-value
Testosterone, nmol/L 11.3 (3.7) 11.5 (4.0) 0.840
SHBG, nmol/L 29 (23–36) 33 (27–44) 0.058
Free testosterone, % 37 (29–46) 33 (27–39) 0.066
Prolactin, μg/ml 8.6 (4.2) 8.1 (3.3) 0.400
LH, IU/l 4.0 (2.4) 3.6 (1.7) 0.243
FSH, IU/l 6.4 (5.3) 5.9 (3.3) 0.501
Leukocytes, 109 /L 7.6 (1.9) 7.6 (1.7) 0.950
Hemoglobin, g /dL 16 (1) 16 (1) 0.257
Platelets, 109 /L 225 (58) 226 (41) 0.886
Glucose, mg /dL 94 (13) 107 (40) 0.024
Total cholesterol, mg /dL 209 (32) 198 (35) 0.059
HDL cholesterol, mg /dL 49 (11) 47 (8.8) 0.239
LDL cholesterol, mg /dl 135 (30) 125 (33) 0.075
Triglycerides, mg /dL 153 (84) 153 (75) 0.980
Proteins, g /dL 7 (0.3) 7 (0.3) 0.760
CRP, mg /L 3.8 (3.3) 5.1 (7) 0.185
Mean (SD) or median (IQR) as appropriate. OSA: obstructive sleep apnea; SHBG: sex hormone binding globulin;
LH: luteinizing hormone; FSH: follicle-stimulating hormone; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; CRP: C-reactive protein
 Independent samples Student’s t test or Mann-Whitney U test as appropriate
https://doi.org/10.1371/journal.pone.0201930.t002
Table 3. Erectile function and self-esteem and relationship scores of OSA patients according to erectile dysfunc-
tion (ED) presence.
non-ED
n = 73
ED
n = 77
p-value
IIEF15
Erectile function 29 (27–30) 18 (6–22) <0.001
Orgasmic function 10 (9–10) 8 (3–10) <0.001
Sexual desire 7 (6–9) 6 (4–7) <0.001
Sexual satisfaction 12 (11–13) 8 (4–11) <0.001
Overall satisfaction 8 (8–9) 6 (4–8) <0.001
SEAR
Sexual relations 81 (72–88) 63 (50–72) <0.001
Self-confidence 75 (67–83) 63 (46–79) <0.001
Self-esteem 75 (59–81) 56 (44–75) 0.002
Relations 88 (75–100) 75 (50–100) 0.001
Total score 78 (71–86) 62 (50–77) <0.001
Median (IQR). OSA: obstructive sleep apnea; IIEF15: International Index Erectile Function test; SEAR: Self-esteem
and Relationship test
 Mann-Whitney U test
https://doi.org/10.1371/journal.pone.0201930.t003
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undergoing pharmacological treatment and had higher glucose levels than patients without
ED. Although after 3 months of CPAP treatment patients improved on erectile function, sex-
ual satisfaction and overall satisfaction, only changes in sexual satisfaction were significantly
different than changes in the control group. Changes in erectile function among study arms
were on the borderline of statistical significance, likely due to difficulties in achieving the
planned sample size. Finally, CPAP treatment did not have any relevant impacts on the psy-
chological, hormonal or biochemical profiles of OSA patients with ED.
The prevalence of ED among newly diagnosed OSA patients in our study was 51%. This
prevalence was lower than those reported by Budweiser (69%) [7] and Giner (69%) [20]. These
differences could be explained by the inclusion in previous studies of patients with known ED
risk factors, such as uncontrolled or advanced chronic conditions, drug addiction, or age
greater than 70 years. As expected and according to the previous literature, we found a higher
ED prevalence among the oldest patients. Similarly, ED patients more commonly used drugs,
specifically hypolipidemic, angiotensin-converting enzyme inhibitors and oral antidiabetics.
Differences in WHR, but not in weight or BMI, were found, in agreement with studies show-
ing that central obesity is an independent ED risk factor [21,22]. The absence of differences in
the biochemical profiles of OSA patients with and without ED validated the decision to
exclude all patients with uncontrolled cardiovascular risk factors for ED. Regarding hormonal
profiles, ED patients had slightly higher sHBG and lower free testosterone levels than non-ED
patients. These differences were most likely explained by age differences because plasma sHBG
Table 4. Effect of CPAP treatment on the erectile function of OSA patients with ED.
IIEF15 non-CPAP (n = 27) CPAP (n = 30) p-value†
Baseline Follow-up Change p-value Baseline Follow-up Change p-value
Erectile function 15.7 (9.1) 17.9 (9.1) +2.1 (5.9) 0.024 15.2 (7.9) 19.8 (9.0) +4.6 (7.9) 0.002 0.060
Orgasmic function 6.2 (4.0) 6.5 (3.9) +0.3 (3.8) 0.911 6.8 (3.4) 7.3 (3.5) +0.4 (3.6) 0.213 0.413
Sexual desire 5.3 (2.4) 5.9 (2.2) +0.6 (1.5) 0.057 5.6 (1.4) 6.2 (2.0) +0.6 (1.7) 0.102 0.968
Sexual satisfaction 7.6 (4.5) 7.9 (4.9) +0.3 (4.1) 0.238 7.2 (4.1) 9.4 (4.7) +2.1 (4.3) 0.003 0.027
Overall satisfaction 5.7 (2.5) 6.0 (2.4) +0.4 (1.6) 0.259 6.3 (2.4) 7.3 (2.3) +1.0 (2.2) 0.035 0.348
Mean (SD). Intention to treat analysis. Of the 75 randomized patients, 8 non-CPAP and 10 CPAP subjects had no IIEF15 measurements at the end of the follow-up and
were excluded from these analyses. OSA: obstructive sleep apnea; IIEF15: International Index Erectile Function test
 Wilcoxon’s matched-pairs signed-ranks test comparing baseline and final measures
† Wilcoxon’s rank-sum test comparing the changes from baseline to the end of follow-up between non-CPAP and CPAP patients
https://doi.org/10.1371/journal.pone.0201930.t004
Table 5. Effect of CPAP treatment on the self-esteem and relationship scores of OSA patients with ED.
SEAR non-CPAP (n = 27) CPAP (n = 30) p-value†
Baseline Follow-up Change p-value Baseline Follow-up Change p-value
Sexual relations 59 (19) 62 (23) +3 (18) 0.370 59 (24) 64 (21) +5 (21) 0.138 0.602
Self-confidence 62 (23) 66 (17) +4 (21) 0.087 63 (21) 67 (22) +4 (17) 0.083 0.811
Self-esteem 60 (26) 62 (20) +2(23) 0.334 58 (22) 64 (23) +6 (18) 0.054 0.483
Relations 69 (25) 76 (16) +7 (27) 0.193 71 (25) 71 (25) -0 (21) 0.908 0.333
Total score 61 (19) 64 (19) +3 (17) 0.178 60 (20) 64 (18) +4 (18) 0.147 0.810
Mean (SD). Intention to treat analysis. Of the 75 randomized patients, 8 non-CPAP and 10 CPAP subjects had no SEAR measurements at the end of the follow-up and
were excluded from these analyses. OSA: obstructive sleep apnea; SEAR: Self-esteem and Relationship test
 Wilcoxon’s matched-pairs signed-ranks test comparing baseline and final measures
† Wilcoxon’s rank-sum test comparing the changes from baseline to the end of follow-up between non-CPAP and CPAP patients
https://doi.org/10.1371/journal.pone.0201930.t005
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concentration increases and total testosterone decreases with age, leaving less free testosterone
available [23]. Finally, although some studies have suggested that OSA could be related to dys-
function in the hypothalamic-pituitary axis [24], no differences in prolactin, LH or FSH levels
were found, probably due to hormonally active testosterone levels being within normal ranges
and gonadotrophins therefore not being activated.
Although improvements in erectile function, sexual satisfaction and overall satisfaction
were found after 3 months of CPAP treatment, only the change in sexual satisfaction was sig-
nificantly different between study arms while changes in erectile function were on the border-
line of statistical significance. After CPAP treatment, the IIEF15 erectile function score was
19.8, which was almost the same as that reported by Taskin in 2010, after 1 month of CPAP
treatment [25], and it did not reach the 25 points that is the threshold for normal values. Other
studies to date have reported different degrees of ED improvement after CPAP treatment
[7,26–35]. It is noteworthy that the most similar previous study in terms of design, an RCT
assessing the effect of 3 months of CPAP / sham CPAP on IIEF15 domains by Melehan et al in
2018, showed a similar increase in sexual satisfaction and non-significant changes on erectile
function [27]. Both RCT [29,31] and observational [28,30,35] studies assessing the short-term
(1 to 3 months) effect of CPAP on ED as measured by IIEF5, that cannot assess the different
domains of ED, have reported moderately positive results, with the exception of Shin et al that
found no effect of CPAP treatment [32]. On the other hand, the only study assessing long-
term effects of CPAP treatment on ED, an observational study by Budweiser et al using IIEF15
as primary end point, showed that CPAP treatment increased overall IIEF15 score and was
able to halt the decrease in sexual function seen among controls [34]. Treatment with sildenafil
has proved to be more effective than CPAP [31,36,37] in improving ED symptoms in OSA
patients, although the combination of CPAP and sildenafil has been reported to provide some
Table 6. Effect of CPAP treatment on the hormonal and biochemical profiles of OSA patients with ED.
non-CPAP (n = 28) CPAP (n = 32) p-value†
Baseline Follow-up Change p-value Baseline Follow-up Change p-value
Testosterone, nmol/L 11 (4) 12 (3) +0.3 (3.0) 0.358 12 (4) 11 (3) -0.6 (2.4) 0.291 0.131
SHBG, nmol/L 36 (14) 37 (16) +1.3 (8.0) 0.991 37 (15) 34 (16) -2.3 (7.0) 0.077 0.119
Free testosterone, % 35 (15) 35 (13) +0.7 (10.7) 0.545 34 (10) 35 (10) +0.9 (6.8) 0.395 0.801
Prolactin, μg/ml 8.1 (4.1) 7.2 (2.7) -0.9 (3.7) 0.112 7.9 (2.3) 7.5 (2.2) -0.4 (1.9) 0.405 0.340
LH, IU/l 3.5 (1.6) 3.8 (1.9) +0.3 (1.3) 0.144 3.7 (1.9) 3.4 (1.6) -0.3 (1.4) 0.178 0.042
FSH, IU/l 5.4 (2.7) 5.6 (2.7) +0.2 (0.8) 0.160 6.5 (3.9) 6.5 (3.7) +0.0 (0.8) 0.645 0.248
Leukocytes, 109 /L 7.7 (1.8) 7.5 (1.9) -0.2 (2.1) 0.116 7.5 (1.6) 6.9 (1.4) -0.6 (1.2) 0.014 0.830
Haemoglobin, g /dL 16 (0.8) 16 (0.9) +0.1 (0.7) 0.608 16 (1.2) 15 (1.4) -0.3 (0.6) 0.004 0.033
Platelets, 109 /L 235 (40) 226 (45) -8.7 (20) 0.021 219 (39) 214 (42) -4.7 (22) 0.155 0.430
Glucose, mg /dL 100 (27) 100 (23) +0.2 (12) 0.888 106 (37) 105 (32) -0.5 (19) 0.469 0.693
Total cholesterol, mg /dL 195 (28) 201 (38) +6.6 (31) 0.275 197 (39) 191 (38) -6.4 (32) 0.376 0.217
HDL cholesterol, mg /dL 48 (7.8) 48 (8.0) -0.2 (5.4) 0.862 46 (9.2) 47 (9.2) +1.4 (7.1) 0.474 0.641
LDL cholesterol, mg /dl 122 (28) 123 (37) +1 (31) 0.754 123 (37) 118 (33) -5.4 (30) 0.469 0.481
Triglycerides, mg /dL 159 (89) 194 (216) +35 (222) 0.729 142 (61) 151 (81) +9.8 (69) 0.472 0.834
Proteins, g /dL 7.1 (0.3) 7.2 (0.3) +0.0 (0.3) 0.517 7.0 (0.3) 7.0 (0.3) +0.0 (0.2) 0.347 0.739
CRP, mg /L 3.9 (2.9) 3.2 (2.0) -0.7 (2.0) 0.181 5.5 (8.7) 3.1 (2.0) -2.4 (8.3) 0.095 0.809
Mean (SD). Intention to treat analysis. Of the 75 randomized patients, 7 non-CPAP and 8 CPAP subjects had no hormonal and biochemical measurements at the end of
the follow-up and were excluded from this analysis. OSA: obstructive sleep apnea; HDL: high-density lipoprotein; LDL: low-density lipoprotein; CRP: C-reactive protein
 Wilcoxon’s matched-pairs signed-ranks test comparing baseline and final measures
† Wilcoxon’s rank-sum test comparing the changes from baseline to the end of follow-up between non-CPAP and CPAP patients
https://doi.org/10.1371/journal.pone.0201930.t006
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additional improvements [38]. In contrast, the effect of CPAP on sexual satisfaction in our
RCT suggested an increase in the patient’s perception of well-being. Moreover, the positive
effects of CPAP treatment, both in terms of snoring reduction and sleep quality, could have a
positive impact on the partner’s sleep quality and overall intimacy levels. This is a novel and
relevant result because previous studies assessing ED with the abbreviated version of the IIEF
could not assess ED dimensions beyond erectile function [25].
The relationship between OSA and ED is well established [5–7]. Testosterone, which peaks
during the Rapid Eyes Movements (REM) phase, is usually lower in OSA patients due to sleep
fragmentation [39] and, along with repeated hypoxia episodes, could lead to a decrease in pro-
tective nocturnal erectile activity [40]. However, the current study did not find significant dif-
ferences in total or free testosterone levels between non-ED and ED groups. Adequate
compliance with CPAP treatment could potentially reverse or stop the detrimental effects of
OSA on ED. However, in our RCT, patients receiving CPAP treatment did not perform better
than patients in the control arm. This finding could be partially explained by the characteristics
of the included patients, who consulted the hospital because of sleep problems and not ED-
related symptoms. In such patients, questions regarding sexual function (that until that time
had not caused the patient any reason for consultation) could increase awareness of the situa-
tion and promote attitude changes toward any ED-related problems.
Our results emphasize the importance of OSA screening in patients undergoing consulta-
tions for ED, and vice versa, given the high prevalence of ED among OSA patients even after
excluding patients with many known ED risk factors. Accordingly, measurements such as
WHR could be used for the identification of OSA patients at higher risk for ED. In contrast,
CPAP treatment showed limited success in ameliorating ED, suggesting that CPAP treatment
should probably be combined with other therapeutic options, such as weight reduction or sil-
denafil, depending on ED severity, to fully overcome ED. In any case, patients’ awareness of
both OSA and ED could potentially be useful for achieving better treatment adherence.
The current study had several strengths: (i) the inclusion of newly diagnosed OSA patients,
all of whom had undergone complete polysomnography; (ii) the exclusion of patients with
many well-known ED risk factors, such as uncontrolled or advanced chronic conditions, drug
addiction, and age greater than 70 years, in an effort to study OSA-related ED without addi-
tional confounding variables; (iii) comprehensive determination of the profiles of OSA
patients with and without ED, including a broad range of sociodemographic, anthropometric,
lifestyle, hormonal, biochemical, clinical and pharmacological variables; and (iv) the use of an
RCT design to assess the potential effects of CPAP treatment on ED. In contrast, several limita-
tions should be acknowledged: (i) Although having a randomization goal of 126 ED patients,
the study was stopped at 75. The main reasons for not reaching the recruitment goal were,
first, the lower-than-expected prevalence of ED coupled with tight inclusion criteria, causing a
very slow recruitment pace (a planned 2-year study turned out having a 3.5 years recruitment
phase); second, the financial constrains caused by the extended recruitment phase; and third,
the need to avoid biases caused by changes in the personnel assessing the patients. This fact
diminished the statistical power of the RCT, most likely precluding statistical significance of
the differences in changes in erectile function between CPAP and non-CPAP patients. Never-
theless, it is unlikely that increasing the sample size would alter the null results in the psychoso-
cial aspects or hormonal and biochemical profiles investigated; (ii) there were no repeated
measures of hormonal profile. This could cause some degree of measurement error specially in
hormones such as testosterone that are subject to short-term fluctuations; (iii) the RCT phase
of this study had a non-blind design. Although the use of sham CPAP could allow for a blind
design, this option was rejected both to avoid unnecessary discomfort to patients and to avoid
neglecting the potential negative implications of using a medical device while sleeping in
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relation to sexual behavior and/or performance; and, (iv) the Ethics Committee approving the
study precluded the inclusion of sleepy patients (ESS score>10) and limited the follow-up
time to 3 months, as not providing CPAP treatment to sleepy patients or delaying CPAP treat-
ment initiation beyond 3 months in non-sleepy patients is considered unethical. This implied
that the current study could not provide insight into the long-term effects of CPAP treatment
on ED. Moreover, this excluded from the study a part of OSA patients (usually with a more
severe disease). Nevertheless, the inclusion of sleepy patients would most provably favor the
authors hypotheses, enhancing the bonds between OSA and ED, and potentially magnifying
the beneficial effects of CPAP on ED.
To conclude, we found a 51% prevalence of ED among newly diagnosed OSA patients, even
when excluding patients with many known ED risk factors. Age, WHR and pharmacological
treatment were identified as the main differences between OSA patients with and without ED.
Finally, 3 months of CPAP treatment significantly increased sexual satisfaction but had no
impact on the psychological, hormonal or biochemical profiles of patients. Overall, this study
confirms the close relationship between OSA and ED, suggesting the potential usefulness of
ED screening in OSA patients, but could not determine conclusively whether CPAP is an
effective stand-alone ED treatment despite positive results on sexual satisfaction.
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